
NASDAQ OMX Index Snapshot

NASDAQ Biotechnology Index (NBI)





RETURNS [Returns for periods greater than 12 months are										
Period: March 31, 2004 - March 31, 2014	1 Month	3 Months	6 Months	9 Months	12 Months	24 Months	36 Months	60 Months	90 Months	120 Months
NASDAQ Biotechnology Index (NBI)	-10.70%	4.19%	12.79%	36.17%	47.90%	38.82%	33.36%	29.31%	17.13%	12.24%
NASDAQ-100 (NDX)	-2.72%	0.10%	11.73%	23.58%	27.57%	14.24%	15.41%	23.79%	10.91%	9.59%

CALENDAR YEAR RETURNS									[Returns are r	not annualized]
Period: March 31, 2004 - March 31, 2014	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
NASDAQ Biotechnology Index (NBI)	4.19%	65.61%	31.91%	11.81%	15.01%	15.63%	-12.63%	4.58%	1.02%	2.84%
NASDAQ-100 (NDX)	0.10%	34.99%	16.82%	2.70%	19.22%	53.54%	-41.89%	18.67%	6.79%	1.49%

VOLATILITY									[Volatiliti	ies are annualized]
Period: March 31, 2004 - March 31, 2014	1 Month	3 Months	6 Months	9 Months	12 Months	24 Months	36 Months	60 Months	90 Months	120 Months
NASDAQ Biotechnology Index (NBI)	30.14%	29.17%	26.56%	24.07%	24.28%	21.41%	22.99%	21.47%	23.69%	22.72%
NASDAQ-100 (NDX)	12.87%	14.27%	13.09%	12.21%	12.84%	14.34%	17.74%	18.37%	23.91%	22.21%

CALENDAR YEAR VOLATILITY									[Volatilities	are annualized]
Period: March 31, 2004 - March 31, 2014	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
NASDAQ Biotechnology Index (NBI)	29.17%	20.74%	18.75%	25.62%	19.96%	24.60%	35.44%	16.25%	16.58%	18.54%
NASDAQ-100 (NDX)	14.27%	12.37%	15.76%	23.83%	19.50%	26.50%	42.45%	18.72%	15.73%	14.03%

CORRELATION*										
Period: March 31, 2004 - March 31, 2014	1 Month	3 Months	6 Months	9 Months	12 Months	24 Months	36 Months	60 Months	90 Months	120 Months
NASDAQ Biotechnology Index (NBI)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
NASDAQ-100 (NDX)	0.75	0.76	0.74	0.74	0.74	0.72	0.77	0.77	0.81	0.79

* NASDAQ Biotechnology Index (NBI) is used as the benchmark.

Source(s): NASDAQ OMX Global Indexes Research. Bloomberg. FactSet.


DAVID KREIN | HEAD OF RESEARCH, GLOBAL INDEXES | 212.231.5813 | DAVID.KREIN@NASDAQOMX.COM

NASDAQ® and NASDAQ OMX® are registered trademarks of The NASDAQ OMX Group, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. The information contained above is provided for information to buy or sell any security or any representation about the financial condition of any company. Statements regarding NASDAQ-listed companies or NASDAQ proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.


NASDAQ OMX Index Snapshot

NASDAQ Biotechnology Index (NBI)


3-YEAR PERFORMANCE



5-YEAR PERFORMANCE



10-YEAR PERFORMANCE



Source(s): NASDAQ OMX Global Indexes Research. Bloomberg. FactSet.

DAVID KREIN | HEAD OF RESEARCH, GLOBAL INDEXES | 212.231.5813 | DAVID.KREIN@NASDAQOMX.COM

NASDAQ® and NASDAQ OMX® are registered trademarks of The NASDAQ OMX Group, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding NASDAQ-listed companies or NASDAQ proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. PLOVE FROM ASCHINTES PROFESSIONAL IS STRONGLY ADVISED. © 2014. The NASDAQ OMX Group, Inc. All Rights Reserved.